EHA Guidelines on Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults
Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults. Aside from the chronic monocytosis that remains the cornerstone of its diagnosis, the clinical presentation of CMML includes dysplastic features, cytopenias, excess of blasts, or myeloproliferative features including high white blood cell count or splenomegaly. Prognosis is variable, with several prognostic scoring systems reported in recent years, and treatment is poorly defined.
This workshop was part of a series of six workshops, each focused on the published EHA Guidelines. Registration for the full workshop series was free and the on-demand recordings were made available on the platform. The Guidelines Workshops are designed to raise awareness about EHA producing and endorsing existing guidelines. In addition, the Workshops aimed to disseminate good practices and knowledge for diagnosis and treatment of hematologic diseases and illustrate the application of the guidelines in the real world setting.
During the workshop authors of the Guidelines presented an overview of the guidelines, reviewing diagnostic criteria and discussing treatment strategies. Patient cases were presented to illustrate the application of the guidelines in the real-world setting. The workshops were interactively-designed, allowing the audience to participate in polls and submit questions, which were discussed live during the workshop between the panel members.
Live session date: Januari 14, 2021
Live session time: 16:30 - 17:30 CET
Chairs: P Fenaux (France), L Malcovati (Italy)
General Hematologists and Medical Trainees.
- Opening & Welcome
L Malcovati (Italy)
- Overview of the Guidelines
P Fenaux (France)
- Clinical case presentation: How to manage patients with CMML who are not eligible to allogeneic stem cell transplantation
F Rabian (France)
- Clinical case presentation: Bridge To Transplant: Yes Or No?
C Elena (Italy)
- Q&A and panel discussion
Chaired by L Malcovati (Italy)
- Closing Remarks
P Fenaux (France)
In the third workshop, Prof Malcovati welcomed the audience and started the workshop while Prof Feanux discussed the clinical presentation of CMML, the diagnosis and classification based on morphology, immunophenotype, karyotype and mutational analysis and analysed prognostic factors and treatment strategies depending on the CMML risk and non-transplant strategies, but also targeted and drug therapies. Dr Rabian presented a clinical patient case of a CMML patient who was not eligible to allogeneic stem cell transplantation, whereas Dr Elena presented a patient case, focusing on a bridging strategy for a CMML patient eligible for transplant.
Click here to view the EHA guidelines (on HemaSphere)
Participants of the EHA Guidelines Workshop Series received a total of 4 Continuing Medical Education (CME) points. You can no longer receive CME points by watching the recordings of the Guidelines Workshops.